1. A suspension of calcipotriol monohydrate in the form of nanocrystals with a particle size distribution in the range of 200-600 nm, according to the determination of dynamic light scattering, and the suspension further comprises an aqueous phase including a non-ionic, polymeric surfactant in an amount sufficient to prevent aggregation and / or growth crystals of calcipotriol monohydrate nanocrystals. 2. The suspension according to claim 1, where the surfactant is selected from the group consisting of surfactants in the form of poloxamers or polysorbates and polyoxyethylene C1-6alkyl ether. The suspension according to claim 2, where the poloxamer is selected from the group consisting of poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338 and poloxamer 407.4. The suspension according to claim 3, where the surfactant is poloxamer 188.5. The suspension according to claim 2, where the polysorbate is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 61, polysorbate 80 and polysorbate 81.6. The suspension of claim 2, wherein the polyoxyethylene C1-6 alkyl ether is cetomacrogol 1000.7. The suspension according to any one of claims 2 to 6, where the amount of surfactant in the specified aqueous phase is in the range from about 0.6% to about 1.2% of the mass. suspensions. 8. The suspension according to claim 1, where the nanocrystals of calcipotriol monohydrate have an average particle size of 200-350 nm, 350-400 nm or 400-500 nm, as determined by dynamic light scattering. Calcipotriol monohydrate in the form of nanocrystals with a particle size distribution in the range of 200-600 nm, as determined by dynamic light scattering, said nanocrystals can be obtained by a method comprising the steps of (a) reducing the particle size of crystalline calcipotriol monohydrate in the aqueous phase, s1. Суспензия кальципотриола моногидрата в форме нанокристаллов с распределением размера частиц в диапазоне 200-600 нм, по данным опре
